Nonfunctional Pancreatic NET and PET Imaging
Nonfunctional Pancreatic NET and PET Imaging
Predicting aggressive behavior in the group of nonfunctional pancreatic neuroendocrine tumors
 (NF P-NET) remains a difficult problem in clinical practice. At present, the treatment
 planning in P-NET is significantly restricted by the limited results of conventional imaging.
 In addition, increasing use of multidetector computed tomography (MDCT) and magnetic
 resonance imaging (MRI) is increasing the number of NF P-NETs detected. Somatostatin receptor
 scintigraphy (SRS) combined with anatomical imaging are the conventional modalities in
 imaging of P-NET, but by these methods the diagnostic accuracy still remains compromised.
 Furthermore, recently encouraging results have been obtained in P-NET using 68Ga-labelled
 somatostatin analog, DOTA-1-NaI3-octreotide (68Ga-DOTANOC) positron emission
 tomography-computed tomography (PET-CT).

 The aim of the current project is to evaluate the possibility to enhance the diagnostic
 accuracy by using dual trace functional imaging 18F-labelled fluorodeoxyglucose (18F-FDG) and
 68Ga-DOTANOC PET-CT imaging in patients with NF P-NET. The study consists of 20 patients with
 NF P-NET. The patients enrolled in the study will be imaged 68Ga-DOTANOC and 18F-FDG PET-CT
 followed by surgery or follow-up with endoscopic ultrasonography (EUS) biopsies. The data
 will be collected between autumn 2015 and spring 2018.
Inclusion Criteria:

 -  suspicion of nonfunctional P-NET on primary CT (i.e hypervascularity) or MRI

 -  signed informed consent

 Exclusion Criteria:

 -  vulnerable study subjects such as described in Finnish law concerning clinical studies
 (disabled, children, pregnant or breast-feeding women, prisoners) will not be
 included.